Search

Displaying results 3941 - 3950 of 7059 in total
  1. Drug

    Dexfenfluramine

    go.drugbank.com/drugs/DB01191
    ApprovedIllicitWithdrawn

    For a fairly limited time during the middle of the nineties, the US FDA had approved it for use in managing weight loss. … Dexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug.

    Synonyms: d-N-ethyl-α-methyl-m-trifluoromethylphenethylamine
  2. Drug

    Ertugliflozin

    go.drugbank.com/drugs/DB11827
    ApprovedInvestigational

    [A31581] Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018.[L48621] … Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus.

  3. Drug

    Relebactam

    go.drugbank.com/drugs/DB12377
    ApprovedInvestigational

    [A181195,A181207] It includes a piperidine ring which reduces export from bacterial cells by producing a positive charge. … [label] It is considered to be a last-line treatment option and gained FDA approval as part of the combination product RecarbrioⓇ in July 2019.[L7568]

  4. Drug

    Ziftomenib

    go.drugbank.com/drugs/DB17171
    ApprovedInvestigational

    Ziftomenib is a potent and highly selective menin inhibitor. … [A274738] This drug was approved by the FDA on November 13th, 2025, for the treatment of relapsed or refractory acute myeloid leukemia (AML) in adults with a susceptible NPM1 mutation who have no satisfactory

    Synonyms: (s)-4-methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1h-indole-2-carbonitrile, (S)-4-methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno[2,3- d]pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1Hindole-2-carbonitrile
  5. Drug

    Exagamglogene autotemcel

    go.drugbank.com/drugs/DB15572
    ApprovedInvestigational

    Sickle cell disease (SCD) is a genetic disorder characterized by the production of abnormal sickle-shaped red blood cells (called hemoglobin S, HbS) that initiate a pathophysiology resulting in severe … [L10139] Following engraftment, it causes an increase in the production of HbF and a subsequent decrease in HbS.

    Synonyms: from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a
  6. Drug

    Roflumilast

    go.drugbank.com/drugs/DB01656
    ApprovedInvestigational

    Roflumilast is a highly selective phosphodiesterase-4 (PDE4) inhibitor. … [L46541] On December 15, 2023, the FDA approved a new topical foam formulation of roflumilast for the treatment of seborrheic dermatitis in patients aged 9 years and older.[L49281]

  7. Drug

    Ivermectin

    go.drugbank.com/drugs/DB00602
    ApprovedInvestigationalVet approved

    [L31453] Ivermectin itself is a mixture of two avermectins, comprising roughly 90% 5-O-demethyl-22,23-dihydroavermectin A<sub>1a</sub> (22,23-dihydroavermectin B<sub>1a</sub>) and 10% 5-O-demethyl-25-de … (1-methylpropyl)-22,23-dihydro­-25-(1-methylethyl)avermectin A<sub>1a</sub> (22,23-dihydroavermectin B<sub>1b</sub>).

    Categories: Compounds used in a research, industrial, or household setting
  8. Drug

    Etranacogene dezaparvovec

    go.drugbank.com/drugs/DB16791
    ApprovedInvestigational

    The therapy involves a one-time infusion of a viral vector carrying a codon-optimized DNA sequence of the gain-of-function Padua variant of human Factor IX controlled by a liver-specific promotor 1. … after a minor injury or even spontaneously.

  9. Drug

    Urokinase

    go.drugbank.com/drugs/DB00013
    ApprovedInvestigationalWithdrawn

    [A191943] Urokinase remains connected between these 2 chains by a sulfhydryl bond.[A191943] Urokinase was granted FDA approval on 16 January 1978.[L12138]

  10. Drug

    Dofetilide

    go.drugbank.com/drugs/DB00204
    ApprovedInvestigational

    Dofetilide is a class III antiarrhythmic agent that is approved by the Food and Drug Administration (FDA) for the maintenance of sinus rhythm in individuals prone to the formation of atrial fibrillation

    Categories: OCT2 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index